Status:
RECRUITING
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Lead Sponsor:
Ming-Yuan Chen
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This study aims to explore the efficacy and adverse events of reduced-dose radiotherapy (40.2Gy) versus conventional-dose radiotherapy (49.2Gy) to low-risk target volume for chemosensitive intermediat...
Detailed Description
This study intends to enroll low-risk intermediate-stage nasopharyngeal carcinoma patients who achieve CR/PR after induction chemotherapy and whose plasma EBV-DNA level has dropped to 0 or below the l...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
November 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2032
Estimated Enrollment :
346 Patients enrolled
Trial Details
Trial ID
NCT07328854
Start Date
November 20 2025
End Date
June 30 2032
Last Update
January 9 2026
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
2
Fujian Cancer Hospital
Fuzhou, Fujian, China
3
Sun Yat-sen University cancer center
Guangzhou, Guangdong, China
4
the Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China